TVC201 is an exosome-mediated miRNA injectable therapeutic currently in the pre-clinical development stage.  TVC201 has shown good results in animal models for reduction of Cholangiocarcinoma tumors with limited toxicity or other side effects.

About Cholangiocarcinoma

Cholangiocarcinoma (CCA), often called bile duct cancer, is the second most common primary liver cancer in the United States. These tumors arise from cells within the bile duct, both inside and outside the liver. The tumors can then spread locally via the lymphatic system, as well as involve local structures such as the blood vessels feeding the liver. The tumors can be slow-growing and vary in size. Cholangiocarcinoma is often labeled a silent disease because the signs and symptoms can go unnoticed until the cancer is in the advanced stage. The survival times of CCA patients is usually measured in months, and there are few therapeutic treatment options.This form of cancer is slightly more common in males than females, and usually affects patients who are between 50-70 years of age. 

Please see for more:

http://www.hopkinsmedicine.org/liver_tumor_center/conditions/bile_duct_cancer.html 

Additional resources:

https://rarediseases.info.nih.gov/gard/6042/intrahepatic-cholangiocarcinoma/resources/1

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1877058/

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888819/

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1913093/